EW vs LIVN
EW: Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. LIVN: LivaNova is a medical device company specializing in advanced therapies for cardiac surgery and neurological disorders, including epilepsy and sleep apnea.
Side-by-side fundamentals
| Metric | EW | LIVN | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $88.40 | $78.44 | |
| Market cap | $51.0B | $4.3B | |
| P/E as of 2026-10-21 | 51.40 | 23.14 | LIVN lower |
| Net margin FY2025, SEC XBRL | +17.7% | -17.5% | EW higher |
| Gross margin FY2025, SEC XBRL | +78.0% | +67.7% | EW higher |
| Operating margin FY2025, SEC XBRL | +20.8% | +14.4% | EW higher |
| ROE FY2025, SEC XBRL | +10.4% | -20.2% | EW higher |
| ROA FY2025, SEC XBRL | +7.8% | -9.3% | EW higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.06 | 0.22 | EW lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.6% | +10.7% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +10.8% | Tie |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.54 | 0.94 | |
| 1-year return as of 2026-10-21 close | +16.3% | +43.4% | LIVN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.